Table 3. Clinical characteristics of patients with familial sarcoidosis by sex.

Characteristics	Men N=28	Women N=40	P value
Age (y) at diagnosis	45.4±13.5	51.1±13.9	0.099
BMI at diagnosis, median (IQR)*	27.8 (24.7–32.4)	26.6 (23.2–29.0)	0.310
Smoking
No smoking	17 (60.7)	30 (75.0)	0.210
History of smoking	5 (17.9)	7 (17.5)	0.970
Active smoking	6 (21.4)	3 (7.5)	0.146
Follow-up -time (y), median (IQR)	3.5 (2.1–8.3)	3.7 (1.9–8.7)	0.862
Follow-up <2 y	7 (25.0)	11 (27.5)	0.818
Follow-up 2–5 y	12 (42.9)	14 (35.0)	0.512
Follow-up >5 y	9 (32.1)	15 (37.5)	0.649
Follow-up -time (treatment completed) (y), median (IQR)†	3.5 (2.0–8.2)	3.1 (1.7–7.3)	0.657
Manifestation
Lungs	0 (0.0)	4 (10.0)	0.137
Lymph nodes	6 (21.4)	12 (30.0)	0.430
Lungs and lymph nodes	22 (78.6)	22 (55.0)	0.045
Extrapulmonary manifestations	12 (42.9)	24 (60.0)	0.163
Organ involvement (No.)
1	4 (14.3)	11 (27.5)	0.196
≥ 2	24 (85.7)	29 (72.5)	0.196
≥ 3	11 (39.3)	18 (45.0)	0.639
On medication for sarcoidosis	15 (53.6)	25 (62.5)	0.462
Medication for pulmonary sarcoidosis	10 (35.7)	15 (37.5)	0.881
Medication for extra-pulmonary sarcoidosis	5 (17.9)	18 (78.3)	0.020
Sarcoidosis medication
Inhaled corticosteroid	4 (14.3)	4 (10.0)	0.708
Oral corticosteroid	13 (46.4)	25 (62.5)	0.221
Methotrexate	0 (0.0)	5 (12.5)	0.073
Azathioprine	1 (3.6)	2 (5.0)	1.000
Infliximab	0 (0.0)	1 (2.5)	1.000
Clinical improvement
Follow-up‡	14 (58.3)	10 (27.0)	0.040
Last follow-up§	15 (71.4)	18 (58.1)	0.326
Radiological improvement
Follow-up¶	9 (37.5)	8 (26.7)	0.304
Last follow-up**	14 (66.7)	12 (48.0)	0.203

The data are presented as the number (%) or mean±SD unless otherwise indicated.

^*Data from 21 men and 30 women.

^†Data from 23 men and 32 women.

^‡Data from 24 men and 37 women.

^§Data from 21 men and 31 women.

^¶Data from 24 men and 30 women.

^**Data from 21 men and 25 women.

BMI, body mass index; y, years.